Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2004

01-09-2004 | Review

Biology of recently discovered cytokines: Discerning the pro- and anti-inflammatory properties of interleukin-27

Authors: Alejandro V Villarino, Christopher A Hunter

Published in: Arthritis Research & Therapy | Issue 5/2004

Login to get access

Abstract

IL-27 is a recently identified heterodimeric cytokine produced in response to microbial and host derived inflammatory cues. Initial studies indicated that IL-27 promotes the generation of Th1 responses required for resistance to intracellular infection and unveiled the molecular mechanisms mediating this effect. However, subsequent work uncovered a role for IL-27 in the suppression of Th1 and Th2 responses. Thus, by discussing its pleotropic functions in the context of infection-induced immunity and by drawing parallels to fellow IL-6/IL-12 family cytokines, this review will attempt to reconcile the pro- and anti-inflammatory effects of IL-27.
Appendix
Available only for authorised users
Literature
1.
Boulay JL, O'Shea JJ, Paul WE: Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003, 19: 159-163. 10.1016/S1074-7613(03)00211-5.CrossRefPubMed
2.
Villarino AV, Huang E, Hunter CA: Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004, 173: 715-720.CrossRefPubMed
3.
Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, et al: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002, 16: 779-790. 10.1016/S1074-7613(02)00324-2.CrossRefPubMed
4.
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/ STAT pathway. Biochem J. 1998, 334: 297-314.PubMedCentralCrossRefPubMed
5.
Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M: A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol. 1996, 70: 1143-1153.PubMedCentralPubMed
6.
Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA: IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res. 2003, 23: 513-522. 10.1089/10799900360708632.CrossRefPubMed
7.
Larousserie F, Pflanz S, Coulomb-L'Hermine A, Brousse N, Kastelein R, Devergne O: Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol. 2004, 202: 164-171. 10.1002/path.1508.CrossRefPubMed
8.
Niedobitek G, Pazolt D, Teichmann M, Devergne O: Frequent expression of the Epstein–Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol. 2002, 198: 310-316. 10.1002/path.1217.CrossRefPubMed
9.
Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E: Role of the TRAF binding site and NF-kappaB activation in Epstein–Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 1998, 72: 7900-7908.PubMedCentralPubMed
10.
van Seventer JM, Nagai T, van Seventer GA: Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J Neuroimmunol. 2002, 133: 60-71. 10.1016/S0165-5728(02)00362-4.CrossRefPubMed
11.
Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K: Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood. 2000, 96: 2206-2214.PubMed
12.
Croy BA, He H, Esadeg S, Wei Q, McCartney D, Zhang J, Borzychowski A, Ashkar AA, Black GP, Evans SS, et al: Uterine natural killer cells: insights into their cellular and molecular biology from mouse modelling. Reproduction. 2003, 126: 149-160. 10.1530/rep.0.1260149.PubMedCentralCrossRefPubMed
13.
Devergne O, Coulomb-L'Hermine A, Capel F, Moussa M, Capron F: Expression of Epstein–Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol. 2001, 159: 1763-1776.PubMedCentralCrossRefPubMed
14.
Christ AD, Stevens AC, Koeppen H, Walsh S, Omata F, Devergne O, Birkenbach M, Blumberg RS: An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology. 1998, 115: 307-313.CrossRefPubMed
15.
Omata F, Birkenbach M, Matsuzaki S, Christ AD, Blumberg RS: The expression of IL-12 p40 and its homologue, Epstein–Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis. 2001, 7: 215-220. 10.1097/00054725-200108000-00006.CrossRefPubMed
16.
Gehlert T, Devergne O, Niedobitek G: Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol. 2004, 73: 432-438. 10.1002/jmv.20109.CrossRefPubMed
17.
Nagai T, Devergne O, Mueller TF, Perkins DL, van Seventer JM, van Seventer GA: Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol. 2003, 171: 5233-5243.CrossRefPubMed
18.
Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, Raz E: Cutting edge: Activation of toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol. 2004, 172: 2739-2743.CrossRefPubMed
19.
Smits HH, Van Beelen AJ, Hessle C, Westland R, De Jong E, Soeteman E, Wold A, Wierenga EA, Kapsenberg ML: Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol. 2004, 34: 1371-1380. 10.1002/eji.200324815.CrossRefPubMed
20.
Veckman V, Miettinen M, Pirhonen J, Siren J, Matikainen S, Julkunen I: Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol. 2004, 75: 764-771. 10.1189/jlb.1003461.CrossRefPubMed
21.
Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, Kastelein RA, Saris C, Hunter CA: The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 2003, 19: 645-655. 10.1016/S1074-7613(03)00300-5.CrossRefPubMed
22.
Artis D, Villarino A, Silverman M, He V, Mu S, Summer S, Covey T, Huang E, Yoshida H, Koretzky G, et al: The IL-27R (WSX-1) inhibits innate and adaptive elements of intestinal helminth-induced T helper 2 responses. J Immunol. 2004.
23.
Bancroft AJ, Humphreys NE, Worthington JJ, Yoshida H, Grencis RK: WSX-1: a key role in induction of chronic intestinal nematode infection. J Immunol. 2004, 172: 7635-7641.CrossRefPubMed
24.
Trinchieri G, Pflanz S, Kastelein RA: The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003, 19: 641-644. 10.1016/S1074-7613(03)00296-6.CrossRefPubMed
25.
Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3: 133-146. 10.1038/nri1001.CrossRefPubMed
26.
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoim-mune inflammation of the brain. Nature. 2003, 421: 744-748. 10.1038/nature01355.CrossRefPubMed
27.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, et al: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000, 13: 715-725. 10.1016/S1074-7613(00)00070-4.CrossRefPubMed
28.
Lieberman LA, Cardillo F, Cua D, Rennick D, Kastelein R, Hunter CA: IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004.
29.
Devergne O, Birkenbach M, Kieff E: Epstein–Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997, 94: 12041-12046. 10.1073/pnas.94.22.12041.PubMedCentralCrossRefPubMed
30.
de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, et al: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998, 280: 1435-1438. 10.1126/science.280.5368.1435.CrossRefPubMed
31.
Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998, 280: 1432-1435. 10.1126/science.280.5368.1432.CrossRefPubMed
32.
Taga T, Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997, 15: 797-819. 10.1146/annurev.immunol.15.1.797.CrossRefPubMed
33.
Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, et al: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA. 1996, 93: 407-411. 10.1073/pnas.93.1.407.PubMedCentralCrossRefPubMed
34.
Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, De Waal Malefyt R, Kastelein RA: WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004, 172: 2225-2231.CrossRefPubMed
35.
Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, Whitmore TE, O'Hara PJ, Foster DF: Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun. 1998, 246: 82-90. 10.1006/bbrc.1998.8576.CrossRefPubMed
36.
Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ: Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 2000, 407: 916-920. 10.1038/35038103.CrossRefPubMed
37.
Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, Xia M, Wakeham AC, Nishina H, Potter J, et al: WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 2001, 15: 569-578. 10.1016/S1074-7613(01)00206-0.CrossRefPubMed
38.
O'Shea JJ, Gadina M, Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002, Suppl: S121-S131. 10.1016/S0092-8674(02)00701-8.CrossRef
39.
Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H: Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003, 170: 4886-4890.CrossRefPubMed
40.
Lucas S, Ghilardi N, Li J, de Sauvage FJ: IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA. 2003, 100: 15047-15052. 10.1073/pnas.2536517100.PubMedCentralCrossRefPubMed
41.
Szabo SJ, Sullivan BM, Peng SL, Glimcher LH: Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003, 21: 713-758. 10.1146/annurev.immunol.21.120601.140942.CrossRefPubMed
42.
Murphy KM, Reiner SL: The lineage decisions of helper T cells. Nat Rev Immunol. 2002, 2: 933-944. 10.1038/nri954.CrossRefPubMed
43.
Scott P, Hunter CA: Dendritic cells and immunity to leishmaniasis and toxoplasmosis. Curr Opin Immunol. 2002, 14: 466-470. 10.1016/S0952-7915(02)00353-9.CrossRefPubMed
44.
Artis D, Johnson LM, Joyce K, Saris C, Villarino A, Hunter CA, Scott P: Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol. 2004, 172: 4672-4675.CrossRefPubMed
45.
Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T: Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64: 1152-1156.CrossRefPubMed
46.
Robinson DS, O'Garra A: Further checkpoints in Th1 development. Immunity. 2002, 16: 755-758. 10.1016/S1074-7613(02)00331-X.CrossRefPubMed
47.
Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O'Shea JJ, Frucht DM: Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003, 23: 147-161. 10.1023/A:1023381027062.CrossRefPubMed
48.
Brombacher F, Kastelein RA, Alber G: Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003, 24: 207-212. 10.1016/S1471-4906(03)00067-X.CrossRefPubMed
49.
Holscher C: The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol (Berl). 2003, 193: 1-17. 10.1007/s00430-003-0186-x.CrossRef
50.
Watford WT, Moriguchi M, Morinobu A, O'Shea JJ: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003, 14: 361-368. 10.1016/S1359-6101(03)00043-1.CrossRefPubMed
51.
Ishihara K, Hirano T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13: 357-368. 10.1016/S1359-6101(02)00027-8.CrossRefPubMed
52.
Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J, Wirtz S, Glickman J, Bailey D, Yoshida M, Galle PR, et al: Disruption of T helper 2-immune responses in Epstein–Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA. 2002, 99: 16951-16956. 10.1073/pnas.252648899.PubMedCentralCrossRefPubMed
53.
Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, Takeda A, Zhang M, Hisaeda H, Mak TW, Yoshimura A, et al: WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity. 2003, 19: 657-667. 10.1016/S1074-7613(03)00298-X.CrossRefPubMed
54.
Yamanaka A, Hamano S, Miyazaki Y, Ishii K, Takeda A, Mak TW, Himeno K, Yoshimura A, Yoshida H: Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J Immunol. 2004, 172: 3590-3596.CrossRefPubMed
55.
Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA: Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol. 2000, 1: 70-76. 10.1038/76940.CrossRefPubMed
56.
Lee CK, Smith E, Gimeno R, Gertner R, Levy DE: STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma. J Immunol. 2000, 164: 1286-1292.CrossRefPubMed
57.
Lieberman LA, Banica M, Reiner SL, Hunter CA: STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J Immunol. 2004, 172: 457-463.CrossRefPubMed
58.
Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, Fikrig E, Rincon M: Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity. 2000, 13: 805-815. 10.1016/S1074-7613(00)00078-9.CrossRefPubMed
59.
Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A: In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol. 1996, 157: 798-805.PubMed
60.
Finkelman FD, Shea-Donohue T, Goldhill J, Sullivan CA, Morris SC, Madden KB, Gause WC, Urban JF: Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Annu Rev Immunol. 1997, 15: 505-533. 10.1146/annurev.immunol.15.1.505.CrossRefPubMed
61.
Artis D, Grencia RK: T helper cell cytokine responses during intestinal nematode infection: induction, regulation and effector function. In Parasitic Nematodes: Molecular Biology, Biochemsitry and Immunology. Edited by: Harnett W. 2001, New York: CABI Publishing, 331-371.CrossRef
62.
Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL: Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998, 9: 229-237. 10.1016/S1074-7613(00)80605-6.CrossRefPubMed
63.
Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999, 10: 39-49. 10.1016/S1074-7613(00)80005-9.CrossRefPubMed
64.
Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.CrossRefPubMed
65.
van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB: Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol. 1997, 151: 177-191.PubMedCentralPubMed
66.
Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, Schmitt E, Rude E: Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA. 1995, 92: 4823-4827.PubMedCentralCrossRefPubMed
67.
Leung BP, McInnes IB, Esfandiari E, Wei XQ, Liew FY: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol. 2000, 164: 6495-6502.CrossRefPubMed
68.
Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003, 198: 1951-1957. 10.1084/jem.20030896.PubMedCentralCrossRefPubMed
69.
Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N: Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004, 173: 1171-1178.CrossRefPubMed
70.
de Hooge AS, van de Loo FA, Koenders MI, Bennink MB, Arntz OJ, Kolbe T, van den Berg WB: Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum. 2004, 50: 2014-2023. 10.1002/art.20302.CrossRefPubMed
71.
Ernst M, Inglese M, Waring P, Campbell IK, Bao S, Clay FJ, Alexander WS, Wicks IP, Tarlinton DM, Novak U, et al: Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med. 2001, 194: 189-203. 10.1084/jem.194.2.189.PubMedCentralCrossRefPubMed
Metadata
Title
Biology of recently discovered cytokines: Discerning the pro- and anti-inflammatory properties of interleukin-27
Authors
Alejandro V Villarino
Christopher A Hunter
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1227

Other articles of this Issue 5/2004

Arthritis Research & Therapy 5/2004 Go to the issue

Research article

Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes

Review

Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells

Research article

Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining for cell surface markers

Research article

Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease

Research article

Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]

Research article

Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits